M Lorentzen

957 total citations
9 papers, 29 citations indexed

About

M Lorentzen is a scholar working on Immunology, Epidemiology and Genetics. According to data from OpenAlex, M Lorentzen has authored 9 papers receiving a total of 29 indexed citations (citations by other indexed papers that have themselves been cited), including 6 papers in Immunology, 5 papers in Epidemiology and 5 papers in Genetics. Recurrent topics in M Lorentzen's work include Biosimilars and Bioanalytical Methods (6 papers), Microscopic Colitis (4 papers) and Inflammatory Bowel Disease (4 papers). M Lorentzen is often cited by papers focused on Biosimilars and Bioanalytical Methods (6 papers), Microscopic Colitis (4 papers) and Inflammatory Bowel Disease (4 papers). M Lorentzen collaborates with scholars based in Norway. M Lorentzen's co-authors include Espen A. Haavardsholm, Jørgen Jahnsen, Cato Mørk, Inge Christoffer Olsen, Nils Bolstad, Tore K Kvien, Knut E. A. Lundin, J Hoffmann, Joe Sexton and Guro Løvik Goll and has published in prestigious journals such as Gastroenterology, Annals of the Rheumatic Diseases and Journal of Crohn s and Colitis.

In The Last Decade

M Lorentzen

9 papers receiving 29 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
M Lorentzen Norway	4	20	10	9	7	6	9	29
Mercè Grau‐Pérez Spain	4	29 1.4×	12 1.2×	3 0.3×	25 3.6×	3 0.5×	12	55
Nerea Fernández de Larrea Spain	4	15 0.8×	20 2.0×	8 0.9×	7 1.0×		4	63
Rafał Wojciechowski Poland	4	46 2.3×	13 1.3×	21 2.3×	1 0.1×	3 0.5×	13	67
Chris Thompson United States	3	39 1.9×	8 0.8×	8 0.9×	1 0.1×	4 0.7×	4	74
Chris Nieuwhof Netherlands	4	20 1.0×	9 0.9×		15 2.1×	6 1.0×	5	58
AD Ormerod United Kingdom	3	22 1.1×	2 0.2×	12 1.3×	15 2.1×		7	43
D. Andersone Latvia	3	27 1.4×	7 0.7×	6 0.7×		4 0.7×	4	44
Ellen L. Palmer United States	4	19 0.9×	9 0.9×		4 0.6×	1 0.2×	10	59
Elena Baranova United States	2	36 1.8×	5 0.5×	15 1.7×		3 0.5×	2	40

Countries citing papers authored by M Lorentzen

Since Specialization

Citations

This map shows the geographic impact of M Lorentzen's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by M Lorentzen with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites M Lorentzen more than expected).

Fields of papers citing papers by M Lorentzen

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by M Lorentzen. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by M Lorentzen. The network helps show where M Lorentzen may publish in the future.

Co-authorship network of co-authors of M Lorentzen

This figure shows the co-authorship network connecting the top 25 collaborators of M Lorentzen. A scholar is included among the top collaborators of M Lorentzen based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with M Lorentzen. M Lorentzen is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

9 of 9 papers shown

Lorentzen, M, et al.. (2020). Contact allergy in patients with chronic venous leg ulcers. Contact Dermatitis. 84(6). 470–472. 1 indexed citations

Goll, Guro Løvik, Kristin Kaasen Jørgensen, Joe Sexton, et al.. (2018). AB0442 Long-term safety and efficacy of biosimilar infliximab (CT-P13) after switching from originator infliximab: results from the 26-week open label extension of a norwegian randomised trial. Annals of the Rheumatic Diseases. 77. 1383–1384. 7 indexed citations

Olsen, Inge Christoffer, Nils Bolstad, M Lorentzen, et al.. (2017). THU0354 Disease worsening and safety in patients switching from originator infliximab to biosimilar infliximab (CT-P13) in the randomized nor-switch-study: explorative analysis in SPA patients. Annals of the Rheumatic Diseases. 76. 338–339. 1 indexed citations

Goll, Guro Løvik, M Lorentzen, Nils Bolstad, et al.. (2017). DOP062 Biosimilar infliximab (CT-P13) is not inferior to originator infliximab: explorative IBD subgroup-analyses in Crohn's disease and ulcerative colitis from the NOR-SWITCH trial. Journal of Crohn s and Colitis. 11(suppl_1). S62–S63. 4 indexed citations

Lorentzen, M, Cato Mørk, Jørgen Jahnsen, et al.. (2017). THU0700 Immunogenicity in patients switching from stable originator infliximab treatment to CT-P13: analyses across six diseases from the 52-week randomized nor-switch study. Annals of the Rheumatic Diseases. 76. 472–472. 2 indexed citations

Olsen, Inge Christoffer, Guro Løvik Goll, M Lorentzen, et al.. (2017). Biosimilar Infliximab (CT-P13) is not Inferior to Originator Infliximab: Explorative IBD Subgroup-Analyses in Crohn's Disease and Ulcerative Colitis from the Nor-Switch Trial. Gastroenterology. 152(5). S65–S66. 4 indexed citations

Olsen, Inge Christoffer, Nils Bolstad, M Lorentzen, et al.. (2017). FRI0182 Disease worsening and safety in patients switching from originator infliximab to biosimilar infliximab (CT-P13) in the nor-switch study: explorative analysis of RA patients. Annals of the Rheumatic Diseases. 76. 549–550. 3 indexed citations

Lorentzen, M, et al.. (1985). [Arteritis of the breast].. PubMed. 147(28). 2230–2. 5 indexed citations

Lorentzen, M & J Hoffmann. (1984). Scleroderma of the colon presenting with acute abdominal symptoms.. PubMed. 150(6). 511–2. 2 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact